Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,952 across all filing types
Latest filing 2025-11-13 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
北京先声祥瑞生物制品股份有限公司模拟财务报表审计报告（容诚审字[2025]100Z3532号）
Audit Report / Information Classification · 95% confidence The document is a standalone audit report issued by 容诚会计师事务所 covering the audit opinion, audit basis, key audit matters, auditor responsibilities, and complete audited financial statements (balance sheet, income statement, cash flow, equity changes, and notes). It is not an Annual Report (10-K) or part of a larger corporate report, but rather a dedicated audit report. Therefore, it matches the Audit Report / Information category. Q2 2025
2025-11-13 Chinese
关于披露重组报告书暨一般风险提示公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Leadman Biochemical Co., Ltd. regarding a major asset purchase transaction involving the acquisition of a 70% stake in another company. It references the approval of related proposals by the board and mentions regulatory compliance and risk warnings related to the transaction. The document does not contain financial statements or detailed financial data but serves as a disclosure of the restructuring plan and associated risks. This fits the category of a Capital/Financing Update (CAP) as it relates to a significant financing and restructuring transaction announcement.
2025-11-13 Chinese
董事会关于本次交易符合上市公司重大资产重组管理办法第十一条及不适用第四十三条、第四十四条规定的说明
Regulatory Filings Classification · 95% confidence The document is a detailed explanation by the board of directors regarding a major asset restructuring transaction, specifically a cash purchase of a controlling stake in another company. It references compliance with the "Measures for the Administration of Major Asset Restructurings of Listed Companies" (《上市公司重大资产重组管理办法》), discusses regulatory compliance, asset valuation, and governance implications. The document does not contain financial statements or quarterly/yearly financial results but is a formal board statement about the transaction's compliance and rationale. It is not an announcement of voting results, nor a proxy solicitation, nor a merger proxy statement. It is not a full annual or interim report, nor an earnings release. The document is a regulatory compliance explanation related to a capital transaction (asset acquisition) but does not announce financing or capital structure changes directly. Given the nature of the content, it fits best under Regulatory Filings (RNS) as a compliance disclosure related to a major asset restructuring transaction, but not the transaction announcement itself or a merger filing. The document length is 3310 characters, relatively short, and it is a formal explanatory statement by the board, not a full report or presentation.
2025-11-13 Chinese
董事会关于本次交易履行法定程序的完备性、合规性及提交法律文件有效性的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of Beijing Lideman Biochemical Co., Ltd. regarding the completeness, compliance, and validity of legal documents submitted for a major asset reorganization transaction. It references relevant laws and regulations governing major asset restructurings and confirms that all statutory procedures have been properly followed. The document does not contain financial statements or detailed financial data but rather serves as a legal and procedural compliance statement related to a significant transaction. It is not a full report like an Annual Report or Interim Report, nor is it a simple announcement of a report. It fits best as a Regulatory Filing (RNS) because it is a formal regulatory disclosure about compliance and legal validity of a transaction filing.
2025-11-13 Chinese
北京利德曼生化股份有限公司拟股权收购所涉及的北京先声祥瑞生物制品股份有限公司股东全部权益价值资产评估报告
Regulatory Filings
2025-11-13 Chinese
北京市金杜律师事务所关于北京利德曼生化股份有限公司重大资产购买之法律意见书
M&A Activity Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a major asset purchase transaction involving Beijing Lidman Biochemical Co., Ltd. It includes extensive legal analysis, transaction terms, parties involved, pricing, payment arrangements, performance commitments, and other legal considerations related to a significant asset acquisition. The document references various legal and regulatory frameworks, agreements, and reports but is primarily focused on the legal aspects of a major asset purchase transaction. This type of document is not a financial report, earnings release, or management discussion but a legal opinion related to a major transaction. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids, including major asset purchases and related legal opinions.
2025-11-13 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.